MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-03-2026
Intuitive Surgical Balance Sheet 2011-2026 | ISRG
Annual Balance Sheet Intuitive Surgical
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-3.2 B | -1.88 B | -2.68 B | -1.51 B | -1.22 B | - | -1.17 B | -858 M | -648 M | -1.04 B | -715 M | -600 M | -782 M | -554 M | -466 M |
Long Term Debt |
132 M | 112 M | 64.5 M | 69.6 M | 66.6 M | - | - | - | - | - | - | - | - | - | - |
Long Term Debt Current |
39 M | 33.5 M | 25.3 M | 24.2 M | 20.4 M | 21.9 M | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | 418 M | 339 M | 327 M | 113 M | 95.9 M | 78.8 M | 68 M | 77.5 M | 96.9 M |
Total Current Liabilities |
2.01 B | 1.75 B | 1.66 B | 1.42 B | 1.15 B | 965 M | 1.03 B | 821 M | 704 M | 596 M | 492 M | 501 M | 381 M | 402 M | 321 M |
Total Liabilities |
2.52 B | 2.21 B | 2.04 B | 1.86 B | 1.6 B | 1.41 B | 1.45 B | 1.16 B | 1.03 B | 709 M | 588 M | 580 M | 449 M | 479 M | 418 M |
Deferred Revenue |
507 M | 469 M | 446 M | 397 M | 377 M | 350 M | 338 M | 294 M | 284 M | 241 M | 226 M | 217 M | 200 M | 186 M | 154 M |
Retained Earnings |
7.01 B | 6.8 B | 4.74 B | 3.5 B | 4.76 B | 3.26 B | 2.49 B | 1.52 B | 61.4 M | 1.57 B | 899 M | 488 M | 979 M | 1.33 B | 902 M |
Total Assets |
20.5 B | 18.7 B | 15.4 B | 13 B | 13.6 B | 11.2 B | 9.73 B | 7.85 B | 5.76 B | 6.49 B | 4.91 B | 3.96 B | 3.95 B | 4.06 B | 3.06 B |
Cash and Cash Equivalents |
3.37 B | 2.03 B | 2.77 B | 1.6 B | 1.31 B | 1.64 B | 1.17 B | 858 M | 648 M | 1.04 B | 715 M | 600 M | 782 M | 554 M | 466 M |
Book Value |
17.9 B | 16.5 B | 13.4 B | 11.1 B | 12 B | 9.76 B | 8.28 B | 6.69 B | 4.73 B | 5.78 B | 4.32 B | 3.38 B | 3.5 B | 3.58 B | 2.65 B |
Total Shareholders Equity |
17.8 B | 16.4 B | 13.4 B | 11.1 B | 12 B | 9.76 B | 8.26 B | 6.68 B | 4.73 B | 5.78 B | 4.32 B | 3.38 B | 3.5 B | 3.58 B | 2.65 B |
All numbers in USD currency
Quarterly Balance Sheet Intuitive Surgical
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 66.6 M | - | - | - | 58 M | - | - | - | 68.7 M | 72.2 M | 69.6 M | 71.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
2.31 B | 2.21 B | 2.01 B | 2.21 B | 2.07 B | 1.85 B | 1.78 B | 2.04 B | 2.09 B | - | 1.76 B | 1.86 B | 1.69 B | - | 1.52 B | 1.6 B | 1.48 B | 1.42 B | 1.35 B | 1.41 B | 1.41 B | 1.41 B | 1.41 B | 1.45 B | 1.45 B | 1.45 B | 1.45 B | 1.16 B | 1.16 B | 1.16 B | 1.16 B | 996 M | 996 M | 996 M | 996 M | 709 M | 709 M | 709 M | 709 M | 588 M | 588 M | 588 M | 588 M | 580 M | 580 M | 580 M | 580 M | 449 M | 449 M | 449 M | 449 M | 479 M | 479 M | 479 M | 479 M | 418 M | 418 M | 418 M | 418 M |
Deferred Revenue |
491 M | 500 M | 496 M | 469 M | 426 M | 434 M | 438 M | 446 M | 395 M | - | 418 M | 397 M | 359 M | - | 386 M | 377 M | 348 M | 360 M | 358 M | 350 M | 350 M | 350 M | 350 M | 338 M | 338 M | 338 M | 338 M | 294 M | 294 M | 294 M | 294 M | 244 M | 244 M | 244 M | 244 M | 241 M | 241 M | 241 M | 241 M | 226 M | 226 M | 226 M | 226 M | 217 M | 217 M | 217 M | 217 M | 200 M | 200 M | 200 M | 200 M | 186 M | 186 M | 186 M | 186 M | 154 M | 154 M | 154 M | 154 M |
Retained Earnings |
6.42 B | 7.61 B | 7.14 B | 6.8 B | 6.13 B | 5.58 B | 5.07 B | 4.74 B | 4.21 B | - | 3.4 B | 3.5 B | 4.02 B | - | 4.86 B | 4.76 B | 4.39 B | 4.02 B | 3.51 B | 3.26 B | 3.26 B | 3.26 B | 3.26 B | 2.49 B | 2.49 B | 2.49 B | 2.49 B | 1.52 B | 1.52 B | 1.52 B | 1.52 B | 115 M | 115 M | 115 M | 115 M | 1.57 B | 1.57 B | 1.57 B | 1.57 B | 899 M | 899 M | 899 M | 899 M | 488 M | 488 M | 488 M | 488 M | 979 M | 979 M | 979 M | 979 M | 1.33 B | 1.33 B | 1.33 B | 1.33 B | 902 M | 902 M | 902 M | 902 M |
Total Assets |
19.4 B | 20.2 B | 19.2 B | 18.7 B | 17.7 B | 16.6 B | 15.8 B | 15.4 B | 14.7 B | - | 13.1 B | 13 B | 13.3 B | - | 13.7 B | 13.6 B | 12.9 B | 12.3 B | 11.5 B | 11.2 B | 11.2 B | 11.2 B | 11.2 B | 9.73 B | 9.73 B | 9.73 B | 9.73 B | 7.85 B | 7.85 B | 7.85 B | 7.85 B | 5.78 B | 5.78 B | 5.78 B | 5.78 B | 6.49 B | 6.49 B | 6.49 B | 6.49 B | 4.91 B | 4.91 B | 4.91 B | 4.91 B | 3.96 B | 3.96 B | 3.96 B | 3.96 B | 3.95 B | 3.95 B | 3.95 B | 3.95 B | 4.06 B | 4.06 B | 4.06 B | 4.06 B | 3.06 B | 3.06 B | 3.06 B | 3.06 B |
Cash and Cash Equivalents |
2.81 B | 3.4 B | 2.57 B | 2.03 B | 2.45 B | 3.07 B | 2.87 B | 2.75 B | 3.62 B | 3.46 B | 2.17 B | 1.58 B | 1.55 B | - | 1.12 B | 1.29 B | 1.36 B | 1.62 B | 1.4 B | 1.62 B | 1.62 B | 1.62 B | 1.62 B | 1.17 B | 1.17 B | 1.17 B | 1.17 B | 858 M | 858 M | 858 M | 858 M | 648 M | 648 M | 648 M | 648 M | 1.04 B | 1.04 B | 1.04 B | 1.04 B | 715 M | 715 M | 715 M | 715 M | 600 M | 600 M | 600 M | 600 M | 782 M | 782 M | 782 M | 782 M | 554 M | 554 M | 554 M | 554 M | 466 M | 466 M | 466 M | 466 M |
Book Value |
17 B | 18 B | 17.2 B | 16.5 B | 15.7 B | 14.8 B | 14 B | 13.4 B | 12.6 B | - | 11.3 B | 11.1 B | 11.6 B | - | 12.2 B | 12 B | 11.5 B | 10.9 B | 10.2 B | 9.76 B | 9.76 B | 9.76 B | 9.76 B | 8.28 B | 8.28 B | 8.28 B | 8.28 B | 6.69 B | 6.69 B | 6.69 B | 6.69 B | 4.78 B | 4.78 B | 4.78 B | 4.78 B | 5.78 B | 5.78 B | 5.78 B | 5.78 B | 4.32 B | 4.32 B | 4.32 B | 4.32 B | 3.38 B | 3.38 B | 3.38 B | 3.38 B | 3.5 B | 3.5 B | 3.5 B | 3.5 B | 3.58 B | 3.58 B | 3.58 B | 3.58 B | 2.65 B | 2.65 B | 2.65 B | 2.65 B |
Total Shareholders Equity |
16.9 B | 17.8 B | 17.1 B | 16.4 B | 15.7 B | 14.8 B | 14 B | 13.3 B | 12.6 B | 12 B | 11.3 B | 11 B | 11.6 B | - | 12.2 B | 11.9 B | 11.5 B | 10.8 B | 10.2 B | 9.73 B | 9.73 B | 9.73 B | 9.73 B | 8.26 B | 8.26 B | 8.26 B | 8.26 B | 6.68 B | 6.68 B | 6.68 B | 6.68 B | 4.78 B | 4.78 B | 4.78 B | 4.78 B | 5.78 B | 5.78 B | 5.78 B | 5.78 B | 4.32 B | 4.32 B | 4.32 B | 4.32 B | 3.38 B | 3.38 B | 3.38 B | 3.38 B | 3.5 B | 3.5 B | 3.5 B | 3.5 B | 3.58 B | 3.58 B | 3.58 B | 3.58 B | 2.65 B | 2.65 B | 2.65 B | 2.65 B |
All numbers in USD currency
Balance Sheet is a fundamental financial report of Intuitive Surgical, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.
For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.
Features of balance sheet analysis- Vertical and horizontal analysis
Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods. - Asset quality
It is important to evaluate not only the amount of assets but also their liquidity and realizability. - Accounting for off-balance sheet liabilities
Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.
Balance sheet of other industry stocks – Medical instruments
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Ekso Bionics Holdings
EKSO
|
$ 10.0 | - | $ 24.3 M |  USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Haemonetics Corporation
HAE
|
$ 64.68 | -1.45 % | $ 3.26 B | USA |
 |
AtriCure
ATRC
|
$ 31.29 | -0.54 % | $ 1.49 B | USA |
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
The Cooper Companies
COO
|
$ 81.88 | -1.79 % | $ 16.3 B | USA |
 |
Alcon
ALC
|
$ 83.86 | 0.94 % | $ 40.4 B |  Schweiz |
 |
iRhythm Technologies
IRTC
|
$ 131.18 | 4.24 % | $ 4.2 B | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Repro Med Systems
KRMD
|
$ 4.87 | 2.1 % | $ 222 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 106.6 | -1.16 % | $ 2.41 B | USA |
 |
Baxter International
BAX
|
$ 18.81 | -1.16 % | $ 9.65 B | USA |
 |
Masimo Corporation
MASI
|
$ 175.42 | 0.03 % | $ 9.35 B | USA |
 |
Microbot Medical
MBOT
|
$ 2.42 | 1.46 % | $ 24.7 M |  Israel |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Glaukos Corporation
GKOS
|
$ 116.35 | -1.19 % | $ 5.64 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
Harvard Bioscience
HBIO
|
$ 0.57 | 1.06 % | $ 24.2 M | USA |
 |
Becton, Dickinson and Company
BDX
|
$ 173.18 | -0.59 % | $ 49.8 B | USA |
 |
ResMed
RMD
|
$ 256.42 | -0.72 % | $ 37.5 B | USA |
 |
AngioDynamics
ANGO
|
$ 11.02 | -0.18 % | $ 450 M | USA |
 |
BioLife Solutions
BLFS
|
$ 20.75 | 2.85 % | $ 956 M | USA |
 |
Nephros
NEPH
|
$ 3.98 | 2.84 % | $ 41.3 M | USA |
 |
electroCore
ECOR
|
$ 7.86 | 3.29 % | $ 43.3 K | USA |
 |
Envista Holdings Corporation
NVST
|
$ 28.57 | -0.35 % | $ 4.8 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.68 | -0.72 % | $ 20.4 M | USA |
 |
Pulse Biosciences
PLSE
|
$ 18.67 | 3.98 % | $ 1.26 B | USA |
 |
ICU Medical
ICUI
|
$ 142.84 | 0.12 % | $ 3.52 B | USA |
 |
InfuSystem Holdings
INFU
|
$ 9.35 | 1.85 % | $ 193 M | USA |
 |
STERIS plc
STE
|
$ 245.09 | 0.72 % | $ 24.2 B | USA |
 |
Repligen Corporation
RGEN
|
$ 126.1 | 2.47 % | $ 7.03 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 121.93 | -0.18 % | $ 5.44 B | USA |
 |
Merit Medical Systems
MMSI
|
$ 74.25 | -0.8 % | $ 4.39 B | USA |
 |
STAAR Surgical Company
STAA
|
$ 18.76 | -0.85 % | $ 930 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
OraSure Technologies
OSUR
|
$ 3.06 | 2.73 % | $ 228 M | USA |
 |
Pro-Dex
PDEX
|
$ 47.51 | - | $ 156 M | USA |
 |
Utah Medical Products
UTMD
|
$ 66.51 | - | $ 241 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 252.07 | 0.34 % | $ 18.2 B | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 13.56 | 1.92 % | $ 2.7 B | USA |
 |
Stereotaxis
STXS
|
$ 2.17 | 1.4 % | $ 175 M | USA |
 |
Milestone Scientific
MLSS
|
$ 0.28 | -0.53 % | $ 22.3 M | USA |